

Conformational Analysis, Substituent Effect and Structure activity Relationships of 16-Membered Macrodilides

Radhia Mazri¹, Salah Belaidi^{1,*}, Aicha Kerassa¹, Touhami Lanez²

¹Group of Computational and Pharmaceutical Chemistry, LMCE Laboratory, Department of Chemistry, Faculty of Sciences, University of Biskra, 07000, Biskra, Algeria

²VTRS Laboratory, Faculty of Sciences and Technology, University of El-Oued, B.P. 789, 39000, El-Oued, Algeria

*E-mail address: prof.belaidi@laposte.net

ABSTRACT

Electronic structures, Conformational Analysis, effect of the substitution and structure activity Relationships for macrodilides, have been studied by PM3 and ab initio methods. In the present work, the calculated values, namely net charges, bond lengths, MESP, dipole moments, electron-affinities, heats of formation, drug-likeness and QSAR properties, are reported and discussed in terms of the biological activity of macrodilides.

Keywords: Macrodilide; Antibiotic; Structure; Ab initio; PM3; Lipinski rule and QSAR Properties

1. INTRODUCTION

Macrocyclic motifs are commonly found in natural products and pharmaceutical molecules; and thus provide privileged scaffolds for medicinal chemistry programs in modern drug discovery [1,2].

Symmetric macrodilides are present in many natural products with interesting biological activities [3-5], such as antibacterial, antifungal and cytotoxicity that offer both pharmacological and physicochemical advantages over acyclic molecules with regard to modulation of these problematic molecular targets. The physicochemical advantages of macrocycles result from their shape [6] and lower rotatable bond count [7].

The family of macrodilide antibiotics consists of two classes of natural compounds displaying interesting biological properties [8]. The first class consists of 16-membered macrocycles and the second class is a 14-membered macrocycles [9]. QSAR has done much to enhance our understanding of fundamental processes and phenomena in medicinal chemistry and drug design [10-14].

Quantum chemistry methods play an important role in obtaining molecular geometries and predicting various properties [15]. To obtain highly accurate geometries and physical properties for molecules that are built from electronegative elements, expensive ab initio/HF electron correlation methods are required [16-18].

Drug-likeness is a qualitative concept used in drug design, which is estimated from the molecular structure before the substance is even synthesized and tested.

The calculation of drug-like property can give us better assumption of biological activity of certain molecule. The theoretical calculation and maintain of certain properties of a molecule can fulfill the parameters which are essential to show certain biological activity. Lipinski's rule of five (ROF) is a rule of thumb to evaluate drug-likeness or determine a chemical compound with a certain pharmacological or biological activity that would make it a likely orally active drug in humans [19].

The ROF is based on four properties of molecules, namely, molecular weight (MW), logP, number of hydrogen-bond donors (HBD) taken as equivalent to the number of –OH and –NH groups, and the number of hydrogen-bond acceptors (HBA) taken as equivalent to the number of oxygen and nitrogen atoms.

In this work, we have investigated the geometry, electronic structure and substituent effect for macrodiolide. Finally, we have studied some of QSAR proprieties and drug likeness proprieties of a series of macrodiolide derivatives reported in literature.

2. MATERIAL AND METHODS

Initial calculations were optimized using HyperChem 8.03 software [20]. The geometries of macrodiolide and its derivatives were first fully optimized by molecular mechanics, with MM+ force-field (rms = 0.001 Kcal/Å). Further, geometries were fully re-optimized by using PM3 method [21]. In the next step geometries were fully re-optimized by using Ab initio/HF (STO-3G) and ab initio/HF (6-31G).

The calculated results have been reported in the present work. The calculation of QSAR properties is performed by the module (QSAR Properties, version 8.0). QSAR Properties is a module that, together with HyperChem, allows several properties commonly used in QSAR studies to be calculated.

The calculations are empirical, so, generally, are fast. The calculated results have been reported in the present work.

3. RESULTS AND DISCUSSION

3. 1. Conformational analysis of 16-membered α , β -unsaturated macrodiolides

In this part, we propose to study the 16-membered α , β -unsaturated macrodiolides. Then, our objective is to search the favored conformations, on the basis of energy and geometric considerations with statistical calculations using Boltzmann distribution [14]. We have undertaken a conformational study of macrocycle 16 Figure 1, symmetrical which we will design 16s ($n_1 = n_2 = 4$), dissymmetrical which we will design 16d ($n_1 = 3$, $n_2 = 5$), which represent the core group for many antibiotics.

The most stable structures can be characterized by two structural characters: the two α , β -unsaturated ester group, and the two saturated chains Figure 2.




Figure 1. α , β -unsaturated 16 macrodiolide.

Thus, we have obtained six types of conformations which are present in the majority of cases in 8 kcal/mol energy range above the global minimum.

The conformation types are classed from 1 to 6 two types (1, 3, 5), the two planes of two conformational sites α , β -unsaturated ester group were pseudo parallels; but for types (2, 4, 6), the two planes of the two sites are pseudo antiparallel Figure 2.

In 2 kcal/mol difference, the macrocycle 16s is characterized by the first conformer type 4, which is the most favored with 31.3 % rate followed by a type 1 with 20.5 % and type 3 with 19.2 %.

Then, the macrocycle 16d is presented preferably in the type T6 (47.8 %). The percentages of other conformation types are listed in Table 1.




Figure 2. Main conformational types.

Table 1. Energetic difference and Boltzmann population of different conformational types.

Macrodiolide	16 symmetric ($n_1 = n_2 = 3$)			16 dissymmetric ($n_1 = 3, n_2 = 5$)		
	Type	ΔE	%	Type	ΔE	%
to 2 kcal/mol	4	00.00	31.3	6	00.00	47.8
	1	1.74	20.5			
	3	1.99	19.2			
Sup to 2 kcal/mol	6	02.83	15.7	1	4.23	17.1
	5	6.04	7.2	4	5.2	13.5
	2	6.70	6.1	5	7.13	8.4
				2	8.02	6.8
				3	8.31	6.3

ΔE : Energetic difference to the absolute minimum, %: Boltzmann population.

3. 2. Geometric and Electronic Structure of Basic Structure of Symetric 16-membered Macrodiolide (Type 4)

The efficiency of PM3 method may be scrutinized by comparison with the results obtained by more elaborate calculation such as ab initio/HF. Present results concerning from these results a good correlation can be seen between the ab initio, and PM3 for bond lengths, also the charge densities calculated by these methods are approximately similar. The Dihedral angles vary between 2.7 and 175.9 degrees, Table 2.


**Figure 2.** Conformation 3D of most favored conformer of 16 macrodiolide (type 4) (HyperChem).

Table 2. Calculated values of bond lengths of macrodiolide T4.

Bond length	MM	PM3	Ab initio/HF (STO-3G)	Ab initio/HF (6-31G)
C1 – C2	1,358	1,478	1.514	1.475
C2 – C3	1,345	1,336	1.317	1.331
C3 – C4	1,511	1,485	1.524	1.503
C4 – C5	1,541	1,525	1.553	1.542
C5 – C6	1,541	1,523	1.547	1.536
C6 – C7	1,537	1,527	1.549	1.521
C7 – O8	1,409	1,417	1.442	1.454
O8 – C9	1,349	1,385	1.304	1.361
C9–C10	1,358	1,478	1.513	1.475
C10–C11	1,345	1,336	1.317	1.331
C11–C12	1,511	1,485	1.524	1.503
C12–C13	1,541	1,525	1.553	1.542
C13–C14	1,541	1,523	1.547	1.536
C14–C15	1,537	1,527	1.549	1.521
C15–O16	1,409	1,417	1.442	1.454
O16–C1	1,349	1,385	1.404	1.361
C9–O17	1,207	1,214	1.219	1.212
C1–O18	1,207	1,214	1.219	1.212

Table 3. Dihedral angles in degree.

Dihedral angles	Ab initio/HF (STO-3G)	Ab initio/HF (6-31G)
C1-C2-C3-C4	003.662	004.249
C2-C3-C4-C5	104.896	139.285
C3-C4-C5-C6	075.901	053.643

C4-C5-C6-C7	070.096	063.560
C5-C6-C7-O8	175.902	175.929
C6-C7-O8-C9	073.531	121.570
C7-O8-C9-C10	136.749	049.498
O8-C9-C10-C11	178.213	157.982
C9-C10-C11-C12	003.674	004.251
C10-C11-C12-C13	104.833	139.284
C11-C12-C13-C14	075.963	053.647
C12-C13-C14-C15	070.105	063.555
C13-C14-C15-O16	175.899	175.929
C14-C15-O16-C1	073.519	121.584
C15-O16-C1-C2	136.571	049.483
O16-C1-C2-C3	178.248	157.975
O18-C1-C2-C3	002.703	025.024
O18-C1-O16-C15	044.344	133.348
O17-C9-O8-C7	044.148	133.330
O17-C9-C10-C11	002.716	025.014

Table 4. Mulliken charges of basic structure of macrodiolide T4.

Macrodiolide	Ab initio/HF (STO-3G)	Ab initio/HF (6-31G)
C1	0.311	0.756
C2	-0.100	-0.293
C3	-0.030	-0.079
C4	-0.115	-0.368
C5	-0.095	-0.334
C6	-0.113	-0.300
C7	0.007	0.024

O8	-0.263	-0.742
C9	0.311	0.755
C10	-0.100	-0.293
C11	-0.030	-0.080
C12	-0.115	-0.368
C13	-0.095	-0.334
C14	-0.113	-0.024
C15	0.007	0.742
O16	-0.263	-0.756
O17	-0.265	-0.541
O18	-0.265	-0.454

The Table 4 shows that the atoms C2, C3, C4, C5, C6, O8, C10, C11, C12, C13, C14, O16, O17 and O18 have negative Mulliken charges which leads to electrophilic substitution, whereas the atom C1, C7, C9 and C15 have positive Mulliken charge which lead to preferential site nucleophilic attack.

3. 3. The molecular electrostatic potential MESP of basic structure (T4)

The molecular electrostatic potential surface MESP which is a plot of electrostatic potential mapped onto the iso-electron density surface simultaneously displays molecular shape, size and electrostatic potential values and has been plotted for both the molecules. Molecular electrostatic potential (MESP) mapping is very useful in the investigation of the molecular structure with its physiochemical property relationships [22-27]. In this study, the electrostatic potentials at the surface are presented by different colors Figure 4.





Figure 4. 3D MESP contour map for 16 macrodiolide molecule.

Red color parts represent the regions of negative electrostatic potential while blue ones represent regions of positive electrostatic potential. Green color parts represent also regions of zero potential. A portion of the molecule that has a negative electrostatic potential is susceptible to electrophilic attack while the positive ones are related to nucleophilic reactivity.

3. 4. Substituent effects on the electronic structure in symmetric 16-membered macrodiolides

Ab initio/HF method with (STO-3G) basis set was used to investigate the effects of a variety of substituents (-CH₃ and -Br) on the electronic and structural properties of macrodiolide. In Table 5 and Table 6, HOMO and LUMO energies, energy gaps ΔE , heat of formation and dipole moments are reported for macrodiolide and its derivatives. The Mulliken charges of macrodiolide and its derivatives are listed in Table 7 and Table 8. The chemical structures of the studied macrodiolide and its derivatives are shown in Figure 5.



Series 1

1. R₁=R₂=R₃=R₄=R₅=R₆=R₇=R₈=R₉=R₁₀=R₁₁=R₁₂=H
2. R₁=R₇=CH₃, R₂=R₃=R₄=R₅=R₆=R₈=R₉=R₁₀=R₁₁=R₁₂=H
3. R₂=R₈=CH₃, R₁=R₃=R₄=R₅=R₆=R₇=R₉=R₁₀=R₁₁=R₁₂=H
4. R₃=R₉=CH₃, R₁=R₂=R₄=R₅=R₆=R₇=R₈=R₁₀=R₁₁=R₁₂=H
5. R₄=R₁₀=CH₃, R₁=R₂=R₃=R₅=R₆=R₇=R₈=R₉=R₁₁=R₁₂=H
6. R₁₁=R₅=CH₃, R₁=R₂=R₃=R₄=R₆=R₇=R₈=R₉=R₁₀=R₁₂=H
7. R₆=R₁₂=CH₃, R₁=R₂=R₃=R₄=R₅=R₇=R₈=R₉=R₁₀=R₁₁=H

Series 2

1. R₁=R₂=R₃=R₄=R₅=R₆=R₇=R₈=R₉=R₁₀=R₁₁=R₁₂=H
2. R₁=R₇=Br, R₂=R₃=R₄=R₅=R₆=R₈=R₉=R₁₀=R₁₁=R₁₂=H
3. R₂=R₈=Br, R₁=R₃=R₄=R₅=R₆=R₇=R₉=R₁₀=R₁₁=R₁₂=H
4. R₃=R₉=Br, R₁=R₂=R₄=R₅=R₆=R₇=R₈=R₁₀=R₁₁=R₁₂=H
5. R₄=R₁₀=Br, R₁=R₂=R₃=R₅=R₆=R₇=R₈=R₉=R₁₁=R₁₂=H
6. R₁₁=R₅=Br, R₁=R₂=R₃=R₄=R₆=R₇=R₈=R₉=R₁₀=R₁₂=H
7. R₆=R₁₂=Br, R₁=R₂=R₃=R₄=R₅=R₇=R₈=R₉=R₁₀=R₁₁=H

Figure 5. Scheme of macrodiolide systems.

Table 5. Energies of macrodiolide and di-methyl substitute macrodiolides.

Compound	System	Heat of formation (kcal/mol)	-HOMO (ev)	LUMO (ev)	ΔE (ev)	$\mu(D)$
1	Macrodiolide	-145.9848	8.3558	6.3538	14.7096	0.0050
2	2,10-dimethyl macrodiolide	-160.20276	8.004333	6.545566	14.5498	0.0017
3	3,11-dimethyl macrodiolide	-165.15367	8.064455	6.459725	14.5499	0.0028
4	4,12-dimethyl macrodiolide	-163.40562	8.565975	6.412447	14.5242	0.0005
5	5,13-dimethyl macrodiolide	-163.43828	8.593216	6.410315	14.9784	0.1075
6	6,14-dimethyl macrodiolide	-163.073115	8.582869	6.421652	15.0035	0.0001
7	7,15-dimethyl macrodiolide	-158.02187	8.419232	6.268329	15.0045	0.0053

Note: Heat of formation by PM3 by HyperChem 8.06. HOMO, LUMO, ΔE and μ by Ab initio/HF (STO-3G).

Table 6. Energies of macrodiolide and di-bromine substitute macrodiolides.

Compound	System	Heat of formation (kcal/mol)	-HOMO (ev)	LUMO (ev)	ΔE (ev)	$\mu(D)$
1	Macrodiolide	-145.9848	8.3558	6.3538	14.7096	0.005
2	2,10-dibrominmacrodiolide	-130.5648	7.5892	5.9869	13.5761	0.0037
3	3,11-dibrominmacrodiolide	-135.1157	7.7678	6.0847	13.8525	0.0035
4	4,12-dibrominmacrodiolide	-163.4098	8.3616	5.7810	14.1426	0.0024
5	5,13-dibrominmacrodiolide	-141.396	8.3204	5.9517	14.2721	4.0813
6	6,14-dibrominmacrodiolide	-164.0099	8.3266	5.9657	14.2923	0004
7	7,15-dibrominmacrodiolide	-140.0745	8.3363	5.9935	14.3298	0.0003

Note: Heat of formation by PM3 by HyperChem 8.06. HOMO, LUMO, ΔE and μ by Ab initio/HF (STO-3G)

The heat of formation is decreased at each addition of di-methyl groups. Compound 3 (3,11-dimethylmacrodiolide) has the smallest value of the heat of formation. This compound (3) is more stable compared to other derivatives.

As has been seen by calculating the effect of a substituent donor increase the energy of the HOMO and that of the LUMO, while we see by calculating the effect of a substituent acceptor decrease the energy of the HOMO and that of the LUMO, Results in a stabilization of the HOMO and LUMO.

In the substituted di-methyl group category, the 4,12-dimethylmacrodiolide (compound 4) has smaller HOMO-LUMO energy gap (14.5242) Table 5 depicts the chemical reactivity of the compound; higher is the HOMO-LUMO energy gap, lesser is the flow of electrons to the higher energy state, making the molecule hard and less reactive. His maximum positive charge on 1stand 9rd position carbon (0.301) which leads to nucleophilic substitution Table 7. On the other hand in smaller HOMO-LUMO gap, there is easy flow of electrons to the higher energy state making it softer and more reactive (HSAB principle: hard and soft acids and bases). Hard bases have highest-occupied molecular orbitals (HOMO) of low energy, and hard acids have lowest-unoccupied molecular orbitals (LUMO) of high energy [28].

Table 7. Mulliken charges of macrodiolide and derivatives (series 1).

Compound	1	2	3	4	5	6	7
C-1	0.311	0.307	0.311	0.301	0.301	0.301	0.305
C-2	-0.100	-0.021	-0.110	-0.112	-0.111	-0.111	-0.102
C-3	-0.030	-0.042	0.047	-0.033	-0.031	-0.031	-0.029
C-4	-0.115	-0.115	-0.118	-0.032	-0.115	-0.113	-0.115
C-5	-0.095	-0.095	-0.096	-0.102	-0.020	-0.102	-0.096
C-6	-0.113	-0.112	-0.113	-0.105	-0.106	-0.024	-0.117
C-7	0.007	0.007	0.005	0.012	0.012	0.009	0.089
O-8	-0.263	-0.265	-0.263	-0.262	-0.262	-0.263	-0.270
C-9	0.311	0.307	0.311	0.301	0.301	0.301	0.305
C-10	-0.100	-0.021	-0.110	-0.112	-0.111	-0.111	-0.102
C-11	-0.030	-0.042	0.047	-0.033	-0.031	-0.301	-0.029
C-12	-0.115	-0.115	-0.118	-0.032	-0.114	-0.113	-0.115
C-13	-0.095	-0.095	-0.096	-0.102	-0.019	-0.102	-0.096
C-14	-0.113	-0.112	-0.113	-0.105	-0.107	-0.024	-0.117
C-15	-0.007	0.007	0.005	0.012	0.011	0.009	0.089
O-16	-0.263	-0.265	-0.263	-0.262	-0.262	-0.263	-0.270
O-17	-0.265	-0.266	-0.271	-0.241	-0.240	-0.241	-0.256
C-18	_____	-0.179	-0.187	-0.176	-0.182	-0.181	-0.203
O-19	-0.265	-0.266	-0.271	-0.241	-0.240	-0.241	-0.256
C-20	_____	-0.179	-0.187	-0.176	-0.181	-0.181	-0.203

Table 8. Mulliken charges of macrodiolide and derivatives (series 2).

Compound	1	2	3	4	5	6	7
C-1	0.311	0.318	0.303	0.313	0.311	0.301	0.308
C-2	-0.100	-0.085	-0.108	-0.092	-0.096	-0.109	-0.100
C-3	-0.030	-0.031	-0.010	-0.032	-0.030	-0.032	-0.027
C-4	-0.115	-0.113	-0.117	-0.080	-0.113	-0.115	-0.116
C-5	-0.095	-0.095	-0.099	-0.097	-0.062	-0.101	-0.098
C-6	-0.113	-0.112	-0.107	-0.113	-0.106	-0.072	-0.103
C-7	0.007	0.011	0.011	0.009	0.011	0.011	0.041
O-8	-0.263	-0.257	-0.259	-0.259	-0.261	-0.257	-0.250
C-9	0.311	0.318	0.303	0.313	0.314	0.301	0.308
C-10	-0.100	-0.085	-0.108	-0.092	-0.096	-0.109	-0.100
C-11	-0.030	-0.031	-0.010	-0.032	-0.032	-0.302	-0.027

C-12	-0.115	-0.113	-0.117	-0.080	-0.118	-0.115	-0.116
C-13	-0.095	-0.095	-0.099	-0.097	-0.062	-0.101	-0.098
C-14	-0.113	-0.112	-0.107	-0.113	-0.113	-0.072	-0.103
C-15	-0.007	0.011	0.011	0.009	0.006	0.011	0.041
O-16	-0.263	-0.257	-0.259	-0.259	-0.252	-0.257	-0.250
O-17	-0.265	-0.256	-0.246	-0.263	-0.242	-0.233	-0.264
Br-18	_____	0.008	0.004	-0.052	-0.058	-0.040	-0.056
O-19	-0.265	-0.256	-0.246	-0.263	-0.288	-0.233	-0.264
Br-20	_____	0.008	0.004	-0.052	-0.058	-0.040	-0.056

The heat of formation is increased at each addition of di-bromine groups except for compound 4 and compound 6 heat of formation is decreased.

Compound 6 (6,14-dibrominmacrodiolide) has the smallest value of the heat of formation. This compound (6) is more stable compared to other derivatives.

As has been seen by calculating the effect of a substituent donor increase the energy of the HOMO and that of the LUMO.

In the substituted di-bromine group category, the 2,10-dibrominmacrodiolide (compound 2) has smaller HOMO-LUMO energy gap (13.5761) Table 6 depicts the chemical reactivity of the compound; higher is the HOMO-LUMO energy gap, lesser is the flow of electrons to the higher energy state, making the molecule hard and less reactive. His maximum positive charge on 1st and 9 rd position carbon (0.318) which leads to nucleophilic substitution Table 8.

3. 5. Study of Structure - activity Relationships for 16-membered Macrodiolides

We have studied seven physical and chemical proprieties of a series of eleven Macrodiolides derivatives Figure 6 using HyperChem 8.03 software. For example, Figure 7 shows the favored conformation in 3D of the Efomycine. We will continue this work in the future by a quantitative calculation.















Figure. 7. 3D Conformation of Efomycine (HyperChem 8.03).

Compound	Structure	References
Pamamycine 607	 <p>The chemical structure of Pamamycine 607 is a complex macrocyclic molecule. It features a 14-membered ring with two oxygen atoms. The ring is substituted with a methyl group (H₃C) on a dashed bond, a methyl group (CH₃) on a wedged bond, a propyl group (H₃C-CH₂-CH₂-) on a dashed bond, and another methyl group (CH₃) on a wedged bond. A side chain is attached to the ring, consisting of a 5-membered ring with an oxygen atom, a methyl group (H₃C) on a dashed bond, a nitrogen atom bonded to two methyl groups (H₃C-N-CH₃), and a propyl group (CH₂-CH₂-CH₃) on a dashed bond.</p>	[52]
Pamamycine 621	 <p>The chemical structure of Pamamycine 621 is a complex macrocyclic molecule, similar to Pamamycine 607. It features a 14-membered ring with two oxygen atoms. The ring is substituted with a methyl group (H₃C) on a dashed bond, a methyl group (CH₃) on a wedged bond, a propyl group (H₃C-CH₂-CH₂-) on a dashed bond, and another methyl group (CH₃) on a wedged bond. A side chain is attached to the ring, consisting of a 5-membered ring with an oxygen atom, a methyl group (H₃C) on a dashed bond, a nitrogen atom bonded to two methyl groups (H₃C-N-CH₃), and a propyl group (CH₂-CH₂-CH₃) on a dashed bond.</p>	[52]
LC-28	 <p>The chemical structure of LC-28 is a complex macrocyclic molecule. It features a 14-membered ring with two oxygen atoms. The ring is substituted with a methyl group (H₃C) on a dashed bond, a methyl group (CH₃) on a wedged bond, a propyl group (H₃C-CH₂-CH₂-) on a dashed bond, and another methyl group (CH₃) on a wedged bond. A side chain is attached to the ring, consisting of a 5-membered ring with an oxygen atom, a methyl group (H₃C) on a dashed bond, a nitrogen atom bonded to two methyl groups (H₃C-N-CH₃), and a propyl group (CH₂-CH₂-CH₃) on a dashed bond.</p>	[53]

Clavosolide	 <p>The structure of Clavosolide is a complex polyketide. It features a central chain with two cyclopropane rings, each substituted with a methyl group. The chain is decorated with several methoxy groups and is terminated by a trimethylsilyloxy group. Stereochemistry is indicated with wedges and dashes.</p>	[54]
Amphidinolide-x	 <p>The structure of Amphidinolide-x is a long-chain polyketide. It contains a central chain with a double bond, a methyl group, and a methyl ketone group. The chain is terminated by a methyl ketone group. Stereochemistry is indicated with wedges and dashes.</p>	[55]
Pyrenophorol	 <p>The structure of Pyrenophorol is a cyclic polyketide. It features a central chain with two double bonds, a methyl group, and a methyl ketone group. The chain is terminated by a methyl ketone group. Stereochemistry is indicated with wedges and dashes.</p>	[56]
Pyrenophorine	 <p>The structure of Pyrenophorine is a cyclic polyketide. It features a central chain with two double bonds, a methyl group, and a methyl ketone group. The chain is terminated by a methyl ketone group. Stereochemistry is indicated with wedges and dashes.</p>	[57]

Vermiculine		[58]
Elaiophylline		[59]
Elaiolide		[60]
Efomycine		[60]

A quantitative characterization based on computed physicochemical property profiles such as Polarizability [29], Partition Coefficient (log P) [30-33], Hydration Energy [34-36], Molecular Volume [37], Molecular Surface and Molecular Mass [38] has been conducted. The physicochemical parameters used in the study are described below.

Molecular Refractivity (MR)

It is the measures of volume occupied by a group of atoms or atoms and is a measure of the susceptibility of the molecule to become polarized. It is a measure of overall bulkiness and is related to London dispersion forces using $MR = 4\pi N\alpha/3$, where N is Avogadro number and α is the polarizability of the molecule. It gives no information about shape [39].

Molecular weight (MW)

Molecular weight descriptor has been used as a descriptor in systems such as transport studies where diffusion is the mode of operation. It is an important variable in QSAR studies pertaining to cross resistance of various drugs in multi-drug resistant cell lines [40].

Octanol/water partition Log p:

Coefficient are widely used to make estimates for membrane penetration and permeability, including gastrointestinal absorption [41,42], blood–brain barrier (BBB) crossing [43,44], and correlations to pharmacokinetic properties [45].

Hansch and Leo reasoned that highly lipophilic molecules will partition into the lipid interior of membranes and will be retained there [46].

LogP values between 0 and 3, constitutes an optimal window for passive drug absorption. A logP value below 0 means that the compound is hydrophilic, and hence it will have a good solubility but it may have poor permeability. Whereas, a logP value far higher than 3 means that the compound is highly lipophilic, hence, tends to favor absorption, and renders the compounds more susceptible to metabolism and/or biliary clearance. The influence of lipophilicity on the metabolic clearance of drugs is attributed mainly to the increased affinity of drugs for the enzymes [47].

Molecular volume

Determines transport characteristics of molecules, such as intestinal absorption or blood-brain barrier penetration. Volume is therefore often used in QSAR studies to model molecular properties and biological activity [48].

Molecular polarizability

Molecular polarizability of a molecule characterizes the capability of its electronic system to be distorted by the external field, and it plays an important role in modeling many molecular properties and biological activities [49].

The hydration Energy

Hydration energy is the physicochemical property that calculated for each molecule is a key factor determining the stability of different molecular conformations [48].

Solvent-accessible surface

Solvent-accessible surface bounded molecular volume and van der Waals-surface-bounded molecular volume calculations are based on a grid method derived by Bodor et al. [50], using the atomic radii of Gavezotti [51].

3. 6. Structural Comparison of the 16-membered Macrolides

Based on our conclusions on the effect of substitution on Macrolides molecules, we chose a series of Macrolides derivatives; some of them have a biological activity [52-60]. Initially, we performed a structural comparison of this series Figure 4. We used molecular mechanics with MM+ force-field and PM3 method to calculate the stable conformations of this series. These molecules have a weak conformational flexibility, with regard to the other macrocycles of macrolide type [61-67].

3. 7. Structure-activity Relationships of 16-membered Macrodilolides

Lipophilicity is a property that has a major effect on solubility, absorption, distribution, metabolism, and excretion properties as well as pharmacological activity. Lipophilicity has been studied and applied as an important drug property for decades. It can be quickly measured or calculated. Lipophilicity has been correlated to many other properties, such as bioavailability, storage in tissues, permeability, and volume of distribution, toxicity, plasma protein binding and enzyme receptor binding [68,69].

Polarizability values are generally proportional to the values of surfaces and of volumes, the decreasing order of polarizability for these studied Macrodilolides is: l'elaiophyline, clavosolide, elaiolide, efomycine, pamamycine 621, pamamycine 607, amphidinolide, LC28, vermiculine, pyrenophorol and pyrenophorine, Table 9. The order of polarizability is approximately the same one for volume and surface. This also is explained by the relation between polarizability and volume, for the relativity non polar molecules. They are directly linked, for the centers of gravity of negative and positive charges in the absence of external fields to coincide, and the dipole moment of the molecule is zero.

The polarizability of a molecule depends only on its volume, which means that the thermal agitation of non-polar molecules does not have any influence on the appearance of dipole moments in these molecules.

On the other hand, for the polar molecules, the polarizability of the molecule does not depend solely on volume but also depends on other factors such as the temperature because of the presence of the permanent dipole [70].

Surface and distribution volume of these molecules are definitely higher than those of more polar molecules like the lipopeptides or beta-lactams. For example, Deleu et al. used Tammo software on the surfactins C13, C14 and C15 having cores similar to the macrolides [71]. They found that their surfaces vary from 129 to 157 Å² [72], contrarily for these macrodilolides derivatives, surfaces vary from 493.94 to 1142.89 Å². These macrodilolides Derivatives has a great variation of distribution volume, in particular clavosolide and elaiophyline which have respective volumes: 2254.00 and 2466.14 Å³ Table 9.

The most important hydration energy in the absolute value is that of the elaiophyline (16.64 kcal/mol) and the weakest is that of amphidinolide X (01.00kcal/mol) Table 9. Indeed, in the biological environments the polar molecules are surrounded by water molecules.

They are established hydrogen bonds between a water molecule and these molecules. The donor sites of the proton interact with the oxygen atom of water and the acceptor sites of the proton interact with the hydrogen atom. The first corresponds to the complex with the strongest hydrogen bond. These hydrated molecules are dehydrated at least partially before and at the time of their interaction. These interactions of weak energy, which we observe in particular between messengers and receivers, are generally reversible [73].

The elaiophylin has eight proton donor sites (8 OH on two alkyl groups) and two proton acceptor sites (2 C=O on the principal cycle). On the contrary, amphidinolide X has only three acceptor sites [3 C=O (2 on the principal cycle and 1 on the alkyl group)] and it does not have proton donor sites. This property supports the first compound, not only by fixing the receiver, but also activates it. It is thus about an agonist. It has as a consequence a better distribution in fabrics. All (log P) of studied molecules have optimal values. For good oral bioavailability, the log P must be greater than zero and less than 3 ($0 < \log P < 3$). For log P too high, the drug has low solubility and a log P too low; the drug has difficulty penetrating the lipid membranes [74]. Pyrenophorol presents the low coefficient of division (1.55) and comes after clavosolide A (1.88).

These molecules possess a good solubility. When the coefficient of division is rather low, it has as a consequence a better gastric tolerance.

Compounds Efomycine and elaiophyline which have, respectively, higher values 8.14 and 7.86; these molecules are the most absorbent products and have important capacities to be dependent on plasmatic proteins.

Table 9. QSAR proprieties for 16-membered macrodiolides.

Macrodiolides	Volume Moléculaire (Å ³)	Surface Moléculaire (Å ²)	Masse Moléculaire (uma)	LogP	Énergie d'hydratation (Kcal/mol)	Polarisabilité (Å ³)
Pamamycine 607	1712.50	861.64	607.87	5.36	4.00	66.61
Pamamycine 621	1714.24	843.68	621.90	5.86	3.80	68.48
LC-28	1101.66	584.32	396.52	3.11	1.42	41.54
Clavosolide	2254.00	1140.89	857.05	1.88	-2.11	85.19
Amphidinolide-x	1304.44	708.29	448.60	4.25	1.00	48.72
Pyrenophorol	865.49	493.24	312.36	1.55	-2.84	31.70
Pyrenophorine	858.42	496.38	308.33	2.35	-3.60	30.59
Vermiculine	1070.75	608.34	392.41	2.21	-1.42	38.11
Elaiophyline	2466.14	1125.10	1026.29	7.86	-16.64	105.69
Elaiolide	1999.44	955.18	796.03	7.70	-9.39	83.86
Efomycine	2109.76	1142.89	728.96	8.14	-9.46	80.08

3. 8. Drug likeness calculation on the basis of Lipinski rule of five

Drug-likeness appears as a promising paradigm to encode the balance among the molecular properties of a compound that influences its pharmacodynamics and pharmacokinetics and ultimately optimizes their absorption, distribution, metabolism and excretion (ADME) in human body like a drug [75,76]. The empirical conditions to satisfy Lipinski's rule and manifest a good oral bioavailability involve a balance between the aqueous solubility of a compound and its ability to diffuse passively through the different biological barriers.

These parameters allow to ascertaining oral absorption or membrane permeability that occurs when the evaluated molecule follows Lipinski's rule of five, evaluated molecule follows Lipinski's rule of five, molecular weight (MW) ≤ 500 Da, an octanol-water partition coefficient log P ≤ 5, H-bond donors, nitrogen or oxygen atoms with one or more hydrogen atoms (HBD) ≤ 5 and H-bond acceptors, nitrogen or oxygen atoms (HBA) ≤ 10.

The above mentioned parameters were calculated for 1-11 and the results were presented in Tables 10. From the data obtained, it was observed that derivatives 3, 5, 6, 7 and 8 were found to obey the Lipinski rule, suggesting that these compounds theoretically would not have problems with oral bioavailability, whereas compounds 1, 2, 4, 9, 10 and 11 were

found doesn't obey the Lipinski rule, suggesting that these compounds theoretically would have problems with oral bioavailability.

There is much evidence that despite having molecular masses that are above 'rule of 5'-compliant small molecules [77], macrocycles can demonstrate drug like physicochemical and pharmacokinetic properties such as good solubility, lipophilicity, metabolic stability and bioavailability.

Table 10. Lipinski's rule of five for drug likeliness of 16-membered macrodiolides.

Compound	MW (Da)	logP	HBD	HBA	No. of violations of Lipinski rule
1	607.87	5.36	0	6	2
2	621.90	5.86	0	8	2
3	396.52	3.11	0	6	0
4	857.05	1.88	0	16	2
5	448.60	4.25	0	6	0
6	312.36	1.55	0	6	0
7	308.33	2.35	2	6	0
8	392.41	2.21	0	8	0
9	1026.29	7.86	8	18	4
10	796.03	7.70	6	12	4
11	728.96	8.14	4	10	2

4. CONCLUSION

The present work studied the molecular proprieties of macrodiolide. The PM3, and ab initio method can be used quite satisfactorily in predicting the chemical reactivity of the molecules and the effect of substitution of either donor or acceptor electron. The 4,12-dimethylmacrodiolide is predicted to be the most reactive with least HOMO-LUMO energy gap (14.5242) of all macrodiolide systems substituted by di-methyl, and in the substituted di-bromine group category, the 2,10-di-bromine macrodiolide has smaller HOMO-LUMO energy gap (13.5761).

The compound efomycine present the higher coefficient of division. This lipophilic compound penetrates in various membranes, including cellular membranes as well as tissues with high lipid content, to arrive at the receptor site. The compounds LC-28, Amphidinolide-x, Pyrenophorol, Pyrenophorine and Vermiculine were found to obey the Lipinski rule, suggesting that these compounds theoretically would not have problems with oral bioavailability, whereas others compounds were found doesn't obey the Lipinski rule, suggesting that these compounds theoretically would have problems with oral bioavailability.

References

- [1] E.M. Driggers, S.P. Hale, J. Lee, N.K. Terrett, *Nat. Rev. Drug Discov.* 7(2008) 608-624.
- [2] J. Mallinson, I. Collins, *Fut. Med. Chem.* 4 (2012) 1409-1438.
- [3] E. J. Kang, E. Lee, *Chem. Rev.* 105 (2005) 4348-4378.
- [4] S. Muthusamy, M. Sivaguru, *Tetrahedron. Lett* 54 (2013) 6810-6813.
- [5] (a) P. Magiatis, D. Spanakis, S. Mitaku, E. Tsitsa, A. Mentis, C.J. Harvala, *Nat. Prod.* 64 (2001)1093-1094; (b) Y. Minami, K. Yoshida, R. Azuma, M. Nishii, J. Inagaki, F. Nohara. *Tetrahedron. Lett.* 33 (1992) 7373-7376; (c) T. Ishida, Y. In, M. Nishii, Y. Minami, *Chem. Lett.* (1994) 1321-1322 ; (d) C. Christner, G. Kullertz, G. Fischer, M. Zerlin, S. Grabley, R. Thiericke, A. Taddei, A.J. Zeeck, *Antibiot.* 51 (1998) 368-371.
- [6] (a) E. M. Driggers, S. P. Hale, J. Lee, N. K. Terrett, *Nat. Rev. Drug Disc.* 7 (2007) 608-624; (b) E. Marsault, M. L. Peterson, *J. Med. Chem.* 54 (2011) 1961-2004.
- [7] D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward, K. D. Kopple, *J. Med. Chem.* 45 (2002) 2615-2623.
- [8] S. Omura, *Macrolide Antibiotics: Chemistry, Biology and Practice*; Academic: New York, 1984, 538.
- [9] J. S. Yadav, U. V. Subba Reddy, B. V. Subba Reddy, *Tetrahedron. Letters* 50 (2009) 5984-5986.
- [10] J. G. Topliss, *Perspect. Drug. Discov. Des.* 1 (1993) 253.
- [11] W. Zhigao, W. Fangqiang, Su. Changhua, Z. Yongling, *J. Comput. Theor. Nanosci.* 10 (2013) 2323-2327.
- [12] A. Eghdami, M. Monajjemi, *Quantum Matter* 2 (2013) 324-331.
- [13] Y. Chen, Di. Xu, M. Yang, *J. Comput. Theor. Nanosci.* 10 (2013) 2916-2919.
- [14] B. Wu, X. Kong, Z. Cao, Y. Pan, Y. Ren, Y. Li, Q. Yang, and F. Lv, *J. Comput. Theor. Nanosci.* 10(2013) 2403-2410.
- [15] M. Ciobanu, L. Preda, D. Savastru, R. Savastru, E. M. Carstea, *Quantum. Matter.* 2 (2013) 60.
- [16] S. Anurag, J. Srashti, A. K. Nagawat, *Quantum. Matter.* 2 2013) 469-473.
- [17] A. Srivastava, N. Saraf, A. K. Nagawat, *Quantum. Matter.* 2 (2013) 401-407.
- [18] A. Srivastava, N. Jain, A. K. Nagawat, *Quantum. Matter.* 2 (2013) 307-313.
- [19] M. Joydeep, Ch. Raja, S. Saikat, V. Anjay, De. Biplab, T. K. Ravi, *Der. Pharma. Chemica* 1(2) (2009) 188-198.
- [20] *HyperChem (Molecular Modeling System) Hypercube, Inc. USA*, (2007).
- [21] J. J. P. Stewart, *J. Comput. Chem.* 10 (1989) 221-264.
- [22] S. Belaidi, M. Laabassi, R. Gree, A. Botrel. *Scientific Study & Research* 4 (2003) 27-38.
- [23] S. Belaidi, N. Melkemi, *Asian Journal of Chemistry* 25 (2013) 4527-4531
- [24] I. Fleming, *Frontier Orbitals and Organic Chemical Reactions* (John Wiley and Sons, New York, 1976, 5-27.

-
- [25] J. S. Murray, K. Sen, *Molecular Electrostatic Potentials, Concepts and Applications* Elsevier, Amsterdam, 1996.
- [26] I. Alkorta, J. J. Perez, *Int. J. Quant. Chem.* 57 (1996) 123.
- [27] E. Scrocco, J. Tomasi, *Adv. Quantum Chem.* 11 (1978) 115.
- [28] F. J. Luque, M. Orozco, P. K. Bhadane, S. R. Gadre, *J. Phys. Chem.* 97 (1993) 9380.
- [27] J. Sponer, P. Hobza, *Int. J. Quant. Chem.* 57 (1996) 959.
- [28] G. L. Miessler., D. A. Tarr. *Inorganic. Chemistry*, 2nd ed, Prentice-Hall Upper Saddle River, NJ, USA. (1999).
- [29] R. P. Verma, A. Kurup, C. Hansch, *Bioorganic & Medicinal Chemistry* 13 (2005) 237-255.
- [30] W. J. Lyman, *Rosenblatt, Eds.; American Chemical Society: Washington. DC.*, 1-1-1-51, (1990).
- [31] A. Sabljic, H. Guesten, J. Hermens, A. Opperhuizen, *Environmental Science & Technology* 27 (1993) 1394-1402.
- [32] C. Hansch, A. J. Leo, *Wiley: New York*, (1979).
- [33] T. Suzuki, Y. Kudo, *Journal of Computer-Aided Molecular Design* 4 (1990) 155-198.
- [34] A. Khalafi-Nezhad, M. N. Soltani Rad, H. Mohabatkar, Z. Asrari, B. Hemmateenejad, *Bioorg. Med. Chem.* 13 (2005) 1931-1938.
- [35] H. Liu, Y.-M. Du, J. F. Kennedy, *Carbohydrate. Polymers.* 68 (2007) 598-600.
- [36] G. E. Chudinov, D. V. Napolov, M. V. Basilevsky, *Chemical. Physics* 160 (1992) 41-54.
- [37] P. D. Leeson, A. M. Davis, *J. Med. Chem.* 47 (2004) 6338-6348.
- [38] M. Yadav, *Bioinformation* 7 (2011) 388-392.
- [39] L. K. Ojha, Ajay M. Chaturvedi, A. Bhardwaj, M. Thakur, A. Thakur, *IJPAC* 3(4) (2013) 417-427.
- [40] M. Yadav, *Bioinformation* .,7(8) (2011) 388-392.
- [41] S. Winiwarter, N. M. Bonham, F. Ax, A. Hallberg, H. Lennerna's, A. Karlen, *J. Med. Chem.* 41 (1998) 4939-4949.
- [42] P. Artursson, J. Karlsson, *Biochem. Biophys. Res. Commun.* 175 (1991) 880-885.
- [43] R. C. Young, R. C. Mitchell, Th. H. Brown, C. R. Ganellin, R. Griffiths, M. Jones, K. K. Rana, D. Saunders, I. R. Smith, N. E. Sore, T. J. Wilks, *J. Med. Chem.* 31 (1988) 656-671.
- [44] H. Van de Waterbeemd, G. Camenisch, G. Folkers, J. R. Chre'tien, O. A. Raevsky, *J. Drug. Target.* 2 (1998) 151-165.
- [45] D. A. Smith, B. C. Jones, D. K. Walker, *Med. Res. Rev.* 16 (1996) 243-266.
- [46] H. Pajouhesh, G. R. Lenz, *Neurotherapeutics* 2 (2005) 541.
- [47] R. Panchagnula, N. S. Thomas, *Int. J. Pharm.* 201 (2000) 131-150.

-
- [48] P. Lalitha, S. Sivakamasundari, *Orient. J. Chem.* 26(1) (2010) 135-141
- [49] J. Wang, X.Q. Xie, T. Hou, X. Xu, *Fast J. Phys. Chem. A.* 24;111(20) (2007) 4443-4448.
- [50] S. Lanners, H. Norouzi-Arasi, Xavier J. Salom-Roig, G. Hanquet, *A. Chimie* 119 (2007) 7216-7219.
- [51] A. Gavezzotti, *J. Am. Chem. Soc.* 105 (1983) 5220-5225.
- [52] O. Germa, N. Kumar, Eric. J. Thomas, *Tetrahedron. Lett.* 42, 30, 23 (2001) 4969-4974.
- [53] H. R. Jois, A. Sarkar, S. Gurusiddaiah, *Antimicrob. Agents Chemother* 30(3) (1986) 458.
- [54] T. K. Chakraborty, V. R. Reddy, A. Kumar, *Tetrahedron. Lett.* 47, 42 (2006) 7435-7438.
- [55] O. Kattnig, E. Furstner, *J. Am. Chem. Soc.* 126 (2004) 15970-15971.
- [56] S. Amigoni, Y. Le Floch, *Tetrahedron: Asymmetry*, 8, 16 (1997) 2827-2831.
- [57] J. Gailliard, Synthèse formelle de la pyrenophorine, Thèse de doctorat en Chimie; université de Rouen.(1990).
- [58] A. Noda, S. Aoyagi, N. Machinaga, Ch. Kibayashi, *Tetrahedron. Lett.* 35, 44 (1994) 8237-8240.
- [59] I. Paterson, J. Man. *Tetrahedron. Lett.* 38, 4 (1997) 695-698.
- [60] R. Barth, J. Mulzer, *Tetrahedron.* 64, 21 (2008) 4718-4735.
- [61] S. Belaidi, M. Omari, *J. Soc. Alger. Chim.* 10 (2000) 31-40,
- [62] S. Belaidi, M. Omari et A. Dibi, *J. Soc. Alger. Chim.* 10(2) (2000) 221.
- [63] S. Belaidi, A. Dibi, M. Omari, *Turk. J. Chem.* 26 (2002) 491-500.
- [64] S. Belaidi, M. Omari, T. Lanez, A. Dibi, *J. Soc. Alger. Chim.* 14 (2004) 27-39
- [65] S. Belaidi., T. Lanez, M. Omari, A. Botrel. *Asian J. Chem.* 17 (2005) 859-870.
- [66] S. Belaidi, M. Laabassi, R. Gree, A. Botrel, *Rev. Roum. Chim.* 50 (2005) 759-765.
- [67] S. Belaidi, D. Harkati, *ISRN Organic Chemistry*, (2011) 594242.
- [68] E. H. Kerns, L. Di, *Academic. Press, USA.* (2008) 43-47.
- [69] V. Pliska, B. Testa, H. van de Waterbeemd, R. Mannhold, H. Kubinyi, H. Timmerman, *Lipophilicity in Drug Action and Toxicology*, Wiley-VCH, Federal Republic of Germany (1996).
- [70] B. Yavorski, A. Detlaf, *Checklist of Physics.* 1980, 376.
- [71] TAMMO Theoretical Analysis of Molecular Membrane Organization, CRC Press, Boca Raton, Florida, USA (1995).
- [72] Deleu M Synthesis of Surfactin Derivatives and Study Their Properties, Thesis Ph.D, FUSAGX, Belgique (2000).

-
- [73] L. B. Kier, *Molecular Orbital Theory in Drug Research*, Academic Press. New York. NY. USA (1981).
- [74] E. H. Kerns, L. Di, *Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization*, Academic Press, USA, (2008) 43-47.
- [75] Ch. A. Lipinski, Franco Lombardo, B. W. Dominy, P. J. Feeney, *Adv. Drug Deliv. Rev.* 64 (2012) 4-17.
- [76] G. Vistoli, A. Pedretti, B. Testa, *Drug. Discov. Today.* 13(7-8) (2008) 285-294.
- [77] C. A. Lipinski, F. Lombardo, B. Dominy, W. P. J. Feeney. *Adv. Drug. Deliv. Rev.* 23 (1997) 3-25.

(Received 01 May 2014; accepted 08 May 2014)